How to manage prasugrel and ticagrelor in daily practice

European Journal of Internal Medicine

Volumn 25, Issue 3, 2014, Pages 213-220

  Bonhomme, Fanny ^a,b   Fontana, Pierre ^a,b   Reny, Jean Luc ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Blood loss; Peri operative period; Pharmacology; Prasugrel; Surgical; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; OMEPRAZOLE; PRASUGREL; TICAGRELOR; ADENOSINE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSFORMATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTESTINE ABSORPTION; MODERATE HEPATIC IMPAIRMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRESCRIPTION; REVIEW; RISK; SEVERE HEPATIC IMPAIRMENT; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREOPERATIVE CARE; RISK FACTOR;

ADENOSINE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; THIOPHENES;

EID: 84896405006     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.01.016     Document Type: Review

References (86)

1. C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 S199 S233
2. A.M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, and R. Paniccia et al. Incidence and clinical impact of dual non-responsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 2008 734 739
3. M. Franchini, and P.M. Mannucci New antiplatelet agents: why they are needed Eur J Intern Med 20 2009 733 738
4. J.M. Siller-Matula, J. Krumphuber, and B. Jilma Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases Br J Pharmacol 159 2010 502 517
5. S. Azmoon, and D.J. Angiolillo Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist Catheter Cardiovasc Interv 81 2013 232 242
6. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
7. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), P.G. Steg, S.K. James, D. Atar, L.P. Badano, and C. Blömstrom-Lundqvist et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
8. L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O.O. Braun, and J.A. Jakubowski et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
9. J.A. Jakubowski, C.D. Payne, J.T. Brandt, G.J. Weerakkody, N.A. Farid, and D.S. Small et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects J Cardiovasc Pharmacol 47 2006 377 384
10. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, and A. Schömig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation 112 2005 2946 2950
11. D.S. Small, Y.G. Li, C.S. Ernest II, J.H. April, N.A. Farid, and C.D. Payne et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent J Clin Pharmacol 51 2011 321 332
12. A. Schömig Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361 2009 1108 1111
13. J.J. v Van Giezen, L. Nilsson, P. Berntsson, B.M. Wissing, F. Giordanetto, and W. Tomlinson et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
14. K. Birkeland, D. Parra, and R. Rosenstein Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor J Blood Med 1 2010 197 219
15. R. Teng, and K. Butler Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects Eur J Clin Pharmacol 66 2010 487 496
16. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, and D.S. Small et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
17. S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O'Donoghue, F.J. Neumann, and A.D. Michelson et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial Circulation 116 2007 2923 2932
18. L. Bonello, M. Pansieri, J. Mancini, R. Bonello, L. Maillard, and P. Barnay et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
19. U.S. Tantry, L. Bonello, D. Aradi, M.J. Price, Y.-H. Jeong, and D.J. Angiolillo et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
20. M.J. Price, J.S. Walder, B.A. Baker, D.E. Heiselman, J.A. Jakubowski, and D.K. Logan et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial J Am Coll Cardiol 59 2012 2338 2343
21. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, and C. Wei et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
22. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
23. L.T. Goodnough, P.K. Smith, J.H. Levy, R.S. Poston, M.A. Short, and G.J. Weerakkody et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis J Thorac Cardiovasc Surg 145 2013 [1077-1082.e4]
24. S.D. Wiviott, E. Braunwald, C.H. McCabe, I. Horvath, M. Keltai, and J.-P.R. Herrman et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
25. M.T. Roe, P.W. Armstrong, K.A.A. Fox, H.D. White, D. Prabhakaran, and S.G. Goodman et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
26. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
27. C. Held, N. Asenblad, J.-P. Bassand, R.C. Becker, C.P. Cannon, and M.J. Claeys et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial J Am Coll Cardiol 57 2011 672 684
28. F. D'Ascenzo, M. Bollati, F. Clementi, D. Castagno, B. Lagerqvist, and J.M. de la Torre Hernandez et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses Int J Cardiol 167 2013 575 584
29. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), P. Kolh, W. Wijns, and N. Danchin et al. Guidelines on myocardial revascularization Eur J Cardiothorac Surg 38 2010 S1 S52 [Suppl.]
30. A.D. Bell, A. Roussin, R. Cartier, W.S. Chan, J.D. Douketis, and A. Gupta et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary Can J Cardiol 27 2011 208 221
31. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K.C. Theodoropoulos, and G. Makris et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
32. G. Parodi, R. Valenti, B. Bellandi, A. Migliorini, R. Marcucci, and V. Comito et al. Comparison of prasugrel and ticagrelor loading doses in STEMI patients: the rapid activity of platelet inhibitor drugs (RAPID) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
33. T. Tada, M. Natsuaki, T. Morimoto, Y. Furukawa, Y. Nakagawa, and R.A. Byrne et al. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2 Circ Cardiovasc Interv 5 2012 381 391
34. S. Cassese, R.A. Byrne, T. Tada, L.A. King, and A. Kastrati Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials Eur Heart J 33 2012 3078 3087
35. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, and C. Tumscitz et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
36. T. Zhang, L. Shen, L. Hu, and B. He Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis J Clin Pharmacol 53 2013 345 351
37. R.E. Wrishko, C.S. Ernest, D.S. Small, Y.G. Li, G.J. Weerakkody, and J.R. Riesmeyer et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
38. D. Erlinge, J. Berg Ten, D. Foley, D.J. Angiolillo, H. Wagner, and P.B. Brown et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial J Am Coll Cardiol 60 2012 2032 2040
39. M.T. Roe, S.G. Goodman, E.M. Ohman, S.R. Stevens, J.S. Hochman, and S. Gottlieb et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel Circulation 128 2013 823 833
40. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, S. Meisel, A.J. Dalby, and F.W. Verheugt et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 2008 1626 1636
41. D.J. Angiolillo, J.J. Badimon, J.F. Saucedo, A.L. Frelinger, A.D. Michelson, and J.A. Jakubowski et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
42. S. James, A. Budaj, P. Aylward, K.K. Buck, C.P. Cannon, and J.H. Cornel et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 122 2010 1056 1067
43. G. Montalescot, and J. Silvain Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation 122 2010 1049 1052
44. M.D. Drepper, L. Spahr, and J.L. Frossard Clopidogrel and proton pump inhibitors - where do we stand in 2012? World J Gastroenterol 18 2012 2161 2171
45. D.L. Bhatt, B.L. Cryer, C.F. Contant, M. Cohen, A. Lanas, and T.J. Schnitzer et al. Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
46. C.S. Kwok, V. Jeevanantham, B. Dawn, and Y.K. Loke No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis Int J Cardiol 167 2013 965 974
47. S.G. Goodman, R. Clare, K.S. Pieper, J.C. Nicolau, R.F. Storey, and W.J. Cantor et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial Circulation 125 2012 978 986
48. V. Ancrenaz, Y. Daali, P. Fontana, M. Besson, C. Samer, and P. Dayer et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability Curr Drug Metab 11 2010 667 677
49. V. Ancrenaz, J. Déglon, C. Samer, C. Staub, P. Dayer, and Y. Daali et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers Basic Clin Pharmacol Toxicol 112 2013 132 137
50. D. Zhou, T.B. Andersson, and S.W. Grimm In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics Drug Metab Dispos 39 2011 703 710
51. R. Teng, P.D. Mitchell, and K.A. Butler Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers Eur J Clin Pharmacol 69 2013 477 487
52. R. Rossini, D. Capodanno, C. Lettieri, G. Musumeci, T. Nijaradze, and M. Romano et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation Am J Cardiol 107 2011 186 194
53. S. Schulz, T. Schuster, J. Mehilli, R.A. Byrne, J. Ellert, and S. Massberg et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur Heart J 30 2009 2714 2721
54. S.S. Naidu, M.W. Krucoff, D.R. Rutledge, V.W. Mao, W. Zhao, and Q. Zheng et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study JACC Cardiovasc Interv 5 2012 626 635
55. Task Force for Preoperative Cardiac Risk Assessment, Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology (ESC), D. Poldermans, J.J. Bax, E. Boersma, and S. De Hert et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery Eur Heart J 30 2009 2769 2812
56. P. Albaladejo, E. Marret, C.M. Samama, J.P. Collet, K. Abhay, and O. Loutrel et al. Non-cardiac surgery in patients with coronary stents: the RECO study Heart 97 2011 1566 1572
57. M.J. Eisenberg, P.R. Richard, D. Libersan, and K.B. Filion Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents Circulation 119 2009 1634 1642
58. L.A. García Rodríguez, L. Cea Soriano, C. Hill, and S. Johansson Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study Neurology 76 2011 740 746
59. J.C.J. Sun, R. Whitlock, J. Cheng, J.W. Eikelboom, L. Thabane, and M.A. Crowther et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies Eur Heart J 29 2008 1057 1071
60. S.F. Aranki, and S.C. Body Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications J Thorac Cardiovasc Surg 138 2009 807 810
61. S. Purkayastha, T. Athanasiou, V. Malinovski, P. Tekkis, R. Foale, and R. Casula et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis Heart 92 2006 531 532
62. S.H. Wilson, P. Fasseas, J.L. Orford, R.J. Lennon, T. Horlocker, and N.E. Charnoff et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting J Am Coll Cardiol 42 2003 234 240
63. E.C. Hansson, M. Dellborg, V. Lepore, and A. Jeppsson Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality Heart 99 2013 116 121
64. J.D. Douketis Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians Thromb Res 108 2002 3 13
65. C.L. Grines, R.O. Bonow, D.E. Casey Jr., T.J. Gardner, P.B. Lockhart, and D.J. Moliterno et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Coll Cardiol 49 2007 734 739
66. F. Bonhomme, F. Hafezi, F. Boehlen, and W. Habre Management of antithrombotic therapies in patients scheduled for eye surgery Eur J Anaesthesiol 30 2013 449 454
67. C. Boustière, A. Veitch, G. Vanbiervliet, P. Bulois, P. Deprez, and A. Laquiere et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline Endoscopy 43 2011 445 461
68. N.S. Gerstein, P.M. Schulman, W.H. Gerstein, T.R. Petersen, and I. Tawil Should more patients continue aspirin therapy perioperatively? Ann Surg 255 2012 811 819
69. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, M. Mayr, A.K. Jaffer, and M.H. Eckman et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S e350S
70. W. Korte, M. Cattaneo, P.G. Chassot, S. Eichinger, C. Heymann von, and N. Hofmann et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC) Thromb Haemost 105 2011 743 749
71. D. Fitchett, C.D. Mazer, J. Eikelboom, and S. Verma Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications Can J Cardiol 29 2013 1042 1047
72. J.F. Tanguay, A.D. Bell, M.L. Ackman, R.D. Bauer, R. Cartier, and W.S. Chan et al. Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Can J Cardiol 23 2013 10.1016/j.cjca.2013.07.001 [pii: S0828-282X(13)00443-1]
73. P.-H. Huang, K.J. Croce, D.L. Bhatt, and F.S. Resnic Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation Crit Pathw Cardiol 11 2012 177 185
74. M.N. Di Minno, M. Milone, P. Mastronardi, P. Ambrosino, A. Di Minno, and A. Parolari et al. Perioperative handling of antiplatelet drugs. A critical appraisal Curr Drug Targets 14 2013 880 888
75. A.N. Rassi, E. Blackstone, M.A. Militello, G. Theodos, M.A. Cavender, and Z. Sun et al. Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery Am J Cardiol 110 2012 485 490
76. S. Savonitto, M. Caracciolo, M. Cattaneo, and S. De Servi Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery J Thromb Haemost 9 2011 2133 2142
77. T.B. Morrison, B.M. Horst, M.J. Brown, M.R. Bell, and P.R. Daniels Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents Catheter Cardiovasc Interv 79 2011 575 582
78. F. Franchi, F. Rollini, A. Muñiz-Lozano, J.R. Cho, and D.J. Angiolillo Cangrelor: a review on pharmacology and clinical trial development Expert Rev Cardiovasc Ther 11 2013 1279 1291
79. J.L. Ferreiro, D. Sibbing, and D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
80. M.J. Price Monitoring platelet function to reduce the risk of ischemic and bleeding complications Am J Cardiol 103 2009 A35A A39A
81. E. Mahla, T.A. Suarez, K.P. Bliden, P. Rehak, H. Metzler, and A.J. Sequeira et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 5 2012 261 269
82. Y. Uchida, F. Mori, H. Ogawa, A. Takagi, and N. Hagiwara Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents J Cardiol 55 2010 362 369
83. A. Zinn, and F. Feit Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting Am J Cardiol 104 2009 C49 C54
84. M. Rossi, G.F. Serraino, A. Spadafora, and A. Renzulli What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve? Interact Cardiovasc Thorac Surg 15 2012 115 121
85. G.Y.H. Lip, K. Huber, F. Andreotti, H. Arnesen, K.J. Airaksinen, and T. Cuisset et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting Thromb Haemost 103 2010 13 28
86. J.A. Spertus, R. Kettelkamp, C. Vance, C. Decker, P.G. Jones, and J.S. Rumsfeld et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809